The Metabolic Syndrome

Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2007, Pages 678-690

  Weber, Michael A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884461828     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3358-5.50044-9     Document Type: Chapter

References (98)

1. Mansah GA, Mokdad AH, Ford E, et al. Obesity, metabolic syndrome, and type 2 diabetes: Emerging epidemics and their cardiovascular implications. Cardiol Clin 2004, 22:485-504.
2. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults 1998, National Institutes of Health. National Heart Lung and Blood Institute, U.S. Department of Health and Human Services, Public Health Service, Bethesda, Md.
3. Eckel RH, Krauss RM American Heart Association Call to Action: Obesity as a major risk factor for coronary heart disease. Circulation 1998, 97:2099-2100.
4. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemic of obesity in the United States. JAMA 2001, 286:1195-1200.
5. The Surgeon General's Call To Action To Prevent and Decrease Overweight and Obesity: 2001 2001, United States Department of Health and Human Services, Public Health Service., U.S. Department of Health and Human Services, Public Health Service. Office of the Surgeon General, Rockville, Md.
6. Story M, Sherwood NE, Himes JH, et al. An after-school obesity prevention program for African-American girls: The Minnesota GEMS pilot study. Ethn Dis 2003, 13(Suppl 1):S54-S64.
7. Mo-suwan L, Pongprapai S, Junjana C, et al. Effects of a controlled trial of a school-based exercise program on the obesity indexes of preschool children. Am J Clin Nutr 1998, 68:1006-1011.
8. Neumark-Sztainer D, Story M, Hannan PJ, et al. New Moves: a school-based obesity prevention program for adolescent girls. Prev Med 2003, 37:41-51.
9. Taylor CB, Fortmann SP, Flora J, et al. Effect of long-term community health education on body mass index. The Stanford Five-City Project. Am J Epidemiol 1991, 134:235-249.
10. Wylie-Rosett J, Swencionis C, Peters MH, et al. A weight reduction intervention that optimizes use of practitioner's time, lowers glucose level, and raises HDL cholesterol level in older adults. J Am Diet Assoc 1994, 94:37-42.
11. Allison D, Fontaine K, Manson J, et al. Annual deaths attributable to obesity in the United States. JAMA 1999, 282:1530-1538.
12. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight and obesity. JAMA 2005, 293:1861-1867.
13. st century. N Engl J Med 2005, 352:1138-1145.
14. Kolata G Still counting on calorie counting. New York Times April 29, 2005, C1.
15. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005, 239:1868-1874.
16. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1529.
17. Ness-Abramof R, Nabriski D, Apovian CM Medical therapy for obesity: Present and future. IMAJ 2004, 6:760-765.
18. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. Obstet Gynecol Surv 2004, 59:822-824.
19. Hertz RP, Unger AN, McDonald M, et al. The impact of obesity on work limitations and cardiovascular risk factors in the U.S. workforce. J Occup Environ Med 2004, 46:1196-1203.
20. Wolf AM, Colditz GA Current estimates of the economic cost of obesity in the United States. Obes Res 1998, 6:97-106.
21. Ogden CL, Troiano RP, Briefel RR, et al. Prevalence of overweight among preschool children in the United States, 1971 through 1994. Pediatrics 1997, 99El.
22. Melnik TA, Rhoades SJ, Wales KR, et al. Overweight school children in New York City: Prevalence estimates and characteristics. Int J Obes Relat Metab Disord 1998, 22:7-13.
23. Ehtisham S, Barrett TG, Shaw NJ Type 2 diabetes mellitus in UK children-an emerging problem. Diabet Med 2000, 17:867-871.
24. Kitagawa T, Owada M, Urakami T, et al. Increased incidence of non-insulin dependent diabetes mellitus among Japanese school children correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 1998, 37:111-115.
25. Wei JN, Sung FC, Lin CC, et al. National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 2003, 290:1345-1350.
26. Weber MA, Neutel JM, Smith DHG Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. JACC 2001, 37:169-174.
27. Hall JE Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994, 23:381-394.
28. Hall JE, Brands MW, Dixon WN, et al. Obesity-induced hypertension renal function and systemic hemodynamics. Hypertension 1993, 22:292-299.
29. Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999, 17:1125-1133.
30. Ribstein J, du Callar G, Mimran A Combined renal effects of overweight and hypertension. Hypertension 1995, 26:610-615.
31. Frohlich ED, Messerli FH, Reisin E, et al. The problem of obesity and hypertension. Hypertension 1983, 5(Suppl III):71-78.
32. Csernus K, Lanyi E, Erhardt E, et al. Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion. Eur J Pediatr 2005, 164:44-49.
33. Ahima RS, Flier JS Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11:327-332.
34. You T, Yang R, Lyles MF, et al. Abdominal adipose tissue cytokine gene expression: Relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2004, 288:E741-E747.
35. Behre CJ, Fagerberg B, Hulten LM, et al. The reciprocal association of adipocytokines with insulin resistance and C-reactive protein in clinically healthy men. Metabolism 2005, 54:439-444.
36. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
37. Fukuda N, Satoh C, Hu WY, et al. Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2001, 19:1651-1658.
38. Weber MA, Smith DHG, Neutel JM Differing roles of body mass and the renin-angiotensin system in mediating the hypertension syndrome. Am J Nephrol 2000, 20:169-174.
39. McFarlane SI, Kumar A, Sowers JR Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 19:30H-37H.
40. Reaven GM, Lithell H, Landserg L Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
41. Zhang R, Reisin E Obesity-hypertension: The effects on cardiovascular and renal systems. Am J Hypertens 2000, 13:1308-1314.
42. Rahmouni K, Correia MLG, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005, 45:9-14.
43. Paolisso G, Tagliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999, 34:1047-1052.
44. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999, 103:253-259.
45. Lowell BB, Shulman GI Mitochondrial dysfunction and type 2 diabetes. Science 2005, 307:384-387.
46. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
47. Sasso FC, Carbonara O, Nasti R, et al. Effects of insulin on left ventricular functions during dynamic exercise in overweight and obese subjects. Eur Heart J 2005, 26:1205-1212.
48. Fornoni A, Raij L Metabolic syndrome and endothelial dysfunction. Curr Hypertension Rep 2005, 7:88-95.
49. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989, 12:573-579. American Diabetes Association.
50. Neutel JM, Smith DHG, Graettinger WF, et al. Heredity and hypertension: Impact on metabolic characteristics. Am Heart J 1992, 124:435-440.
51. Weber MA, Smith DHG, Neutel JM, et al. Cardiovascular and metabolic characteristics of hypertension. Am J Med 1991, 91:4S-10S.
52. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
53. Solymoss BC, Bourassa MG, Lesperance J, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis 2003, 14:207-212.
54. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
55. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
56. Reaven GM Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
57. Graettinger WF, Neutel JM, Smith DHG, et al. Left ventricular diastolic filling alterations in normotensive young adults with a family history of systemic hypertension. Am J Cardiol 1991, 68:51-56.
58. Weber MA, Smith DHG, Neutel JM, et al. Arterial properties of early hypertension. J Human Hypertens 1991, 5:417-423.
59. Grunfeld B, Balzareti M, Romo M, et al. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994, 23(Suppl 1):I12-I15.
60. Csernus K, Lanyi E, Erhardt E, et al. Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion. Eur J Pediatr 2005, 164:44-49.
61. Groop L Genetics of the metabolic syndrome. Br J Nutr 2000, 83:S39-S48.
62. Reisin E, Hutchinson HG Obesity-hypertension: Effects on the cardiovascular and renal system-the therapeutic approach. Hypertension 1999, 206-210. WB Saunders, Philadelphia. S. Oparil, M.C. Weber (Eds.).
63. Schmieder RD, Messerli FH Does obesity influence early target organ damage in hypertensive patients?. Circulation 1993, 87:1482-1488.
64. Licata G, Scaglione R, Capuana G, et al. Hypertension in obese subjects: Distinct hypertensive subgroup. J Hum Hypertens 1990, 4:37-41.
65. Barrett-Connor E, Khaw K Is hypertension more benign when associated with obesity?. Circulation 1985, 72:53-60.
66. Carman WJ, Barrett-Connor E, Sowers M, et al. Hypertension/risk factors: Higher risk of cardiovascular mortality among lean hypertensive individuals in Tecumesh, Michigan. Circulation 1994, 89:703-711.
67. Goldbourt U, Holtzman E, Chen-Mandelzweig L, et al. Enhanced risk of coronary heart disease mortality in lean hypertensive men. Hypertension 1987, 10:22-28.
68. Corry DB, Tuck ML Obesity, hypertension, and sympathetic nervous system activity. Curr Hypertens Rep 1999, 1:119-126.
69. Reims HM, Fossum E, Hoieggen A, et al. Adrenal medullary overactivity in lean, borderline hypertensive young men. Am J Hypertens 2004, 17:611-618.
70. Wassertheil-Smoller S, Fann C, Allman RM, et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Arch Intern Med 2000, 160:494-500.
71. Levine JA, Lanningham-Foster LM, McCrady SK, et al. Interindividual variation in posture allocation: Possible role in human obesity. Science 2005, 307:584-586.
72. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2005, 142:525-531.
73. Marcell TJ, McAuley KA, Traustadottir T, et al. Exercise training is not associated with improved levels of C-reactive protein or adiponectin. Metabolism 2005, 54:533-541.
74. Boden G, Sargrad K, Homko C, et al. Effects of a low-carbohydrate diet on appetite, blood glucose levels and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 2005, 142:403-411.
75. Volek JS, Vanheest JL, Forsythe CE Diet and exercise for weight loss: A review of current issues. Sports Med 2005, 35:1-9.
76. Rolls BJ, Shide DJ, Thorwart ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998, 6:1-11.
77. Anterburn DE, Crane PK, Veenstra DL The efficacy and safety of sibutramine for weight loss: A systematic review. Arch Intern Med 2004, 164:994-1003.
78. Torgerson JS, Boldrin MN, Hauptman J, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care 2004, 27:155-161.
79. Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532-546.
80. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002, 26:262-273.
81. Poirier B, Bidouard JP, Cadrouvele C, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005, 7:65-72.
82. Lee WJ, Huang MT, Wang W, et al. Effects of obesity surgery on the metabolic syndrome. Arch Surg 2004, 139:1088-1092.
83. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.
84. Laaksonen DE, Niskanen L, Lakka HM, et al. Epidemiology and treatment of the metabolic syndrome. Ann Med 2004, 36:332-346.
85. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. Diabetes Prevention Program Research Group.
86. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
87. Barzilay JI, Pressel S, Davis BR, et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: A report from the ALLHAT trial. Am J Hypertens 2004, 17:1A.
88. Dahlof B, Devereus RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002, 359:1004-1010. for the LIFE Study Group.
89. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004, 363:2022-2031. for the VALUE trial group.
90. Horio T, Masaaki S, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005, 18:949-957.
91. Gerstein HC, Yusuf S, Holman R, et al. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial. Diabetologia 2004, 41:1519-1527.
92. Prisant LM Preventing type II diabetes mellitus. J Clin Pharmacol 2004, 44:406-413.
93. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
94. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. for the RENAAL Study Investigators.
95. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. for the Collaborative Study Group.
96. Fliser D, Buchholz K, Haller H Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 31:1103-1107.
97. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143.
98. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: Time for a critical appraisal joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005, 28:2289-2304.